This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 5.26% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?
by Zacks Equity Research
On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.
Strength Seen in Alpine Immune Sciences, Inc. (ALPN): Can Its 7.5% Jump Turn into More Strength?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Talaris (TALS) Down on Patient Death From Renal Transplant Study
by Zacks Equity Research
Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.
Zacks Industry Outlook Highlights Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics
by Zacks Equity Research
Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics have been highlighted in this Industry Outlook article.
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
by Zacks Equity Research
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
5 Stocks to Bet on in an Innovation-Driven Drug Industry
by Kinjel Shah
Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?
by Zacks Equity Research
Here is how Catalyst Pharmaceutical (CPRX) and AxoGen (AXGN) have performed compared to their sector so far this year.
Reata (RETA) Up After FDA Scraps AdCom Meeting for NDA Filing
by Zacks Equity Research
The FDA decides not to hold an advisory committee meeting for Reata Pharmaceuticals' (RETA) regulatory filing seeking approval for omaveloxolone in Friedreich's Ataxia.
Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab
by Zacks Equity Research
Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.
United Therapeutics (UTHR) Initiates Tyvaso Study in IPF
by Zacks Equity Research
United Therapeutics (UTHR) initiates a second phase III study evaluating its Tyvaso inhalation solution. The study will be conducted in sites outside the United States and Canada.
Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why
by Zacks Equity Research
Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.
Is Catalyst Pharmaceuticals (CPRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Catalyst Pharmaceutical (CPRX) and IMARA Inc. (IMRA) have performed compared to their sector so far this year.
Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.
Looking for a Growth Stock? 3 Reasons Why Catalyst (CPRX) is a Solid Choice
by Zacks Equity Research
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
Catalyst (CPRX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Catalyst (CPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Catalyst Pharmaceuticals (CPRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Catalyst Pharmaceutical (CPRX) and Lyell Immunopharma (LYEL) have performed compared to their sector so far this year.
Spectrum Pharmaceuticals (SPPI) Gets Nod for Rolvedon Injection
by Zacks Equity Research
Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia.
Here's How Much You'd Have If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Zacks.com featured highlights include Tsakos Energy, AVEO Pharmaceuticals and Catalyst Pharmaceuticals
by Zacks Equity Research
Tsakos Energy, AVEO Pharmaceuticals and Catalyst Pharmaceuticals have been highlighted in this Screen of The Week article.
Buy These 3 Top Breakout Stocks Now for Superb Returns
by Tirthankar Chakraborty
Tsakos Energy Navigation (TNP), AVEO Pharmaceuticals (AVEO) and Catalyst Pharmaceuticals (CPRX) have been selected as the breakout stocks for today.
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma
by Zacks Equity Research
Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.
Catalyst (CPRX) Up 13.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Pharmaceutical (CPRX) Just Reclaimed the 20-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds
by Zacks Equity Research
Ironwood (IRWD) reports positive top-line data from a late-stage study evaluating Linzess (linaclotide) for functional constipation in pediatric patients aged six to 17 years.